Scinai Immunotherapeutics (SCNI) Gross Margin (2024 - 2026)
Scinai Immunotherapeutics' (SCNI) quarterly Gross Margin came in at 272.17% in Q2 2026, up 52890.0% year-over-year from N/an in Q2 2025, and down 19.05% quarter-over-quarter from 228.63% in Q1 2026.
Powered by 
Analysis
Scinai Immunotherapeutics (SCNI) Gross Margin (2024 - 2026) Analysis & Trends
Scinai Immunotherapeutics has disclosed Gross Margin across 3 years of filings, most recently posting 272.17% for Q2 2026.
- In Q2 2026, Gross Margin rose 52890.0% year-over-year to 272.17%; the TTM figure through Jun 2026 stood at 211.38% (down 6439.0% YoY), while the FY2025 annual figure was 181.41%, down 9327.0% from the prior year.
- Gross Margin came in at 272.17% for Q2 2026 at Scinai Immunotherapeutics, down from 228.63% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 38.91% in Q1 2025 to a low of 801.07% in Q2 2025.
- Average Gross Margin over 3 years is 248.71%, with a median of 188.42% recorded in 2024.
- The largest YoY upside for Gross Margin was 52890 bps in 2026 against a maximum downside of 26754 bps in 2026.
- Over 3 years, Gross Margin stood at 81.07% in 2024, then slumped by 888 bps to 801.07% in 2025, then soared by 66 bps to 272.17% in 2026.
- Per Business Quant data, the three most recent Gross Margin figures were 272.17% in Q2 2026, 228.63% in Q1 2026, and 801.07% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 91.59% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 90.43% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 35.86% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 71.60% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 80.31% |
| 10 | Scinai Immunotherapeutics | 1.52 Bn | 1.52 Bn | -1.25 Mn | -272.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -272.17% |
| Mar 31, 2026 | -228.63% |
| Jun 30, 2025 | -801.07% |
| Mar 31, 2025 | 38.91% |
| Dec 31, 2024 | -81.07% |
| Sep 30, 2024 | -148.21% |